ReviR Therapeutics and Asieris Pharmaceuticals Enter into Agreement to Discover Oncology Therapeutics
ReviR Therapeutics, a privately held developer of a suite of small molecule RNA-targeting technologies for cancer and other genetically-defined diseases, and Asieris Pharmaceuticals, a global biopharma company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, today announced that they have entered into a research collaboration and option-to-license agreement aimed at discovering and developing innovative treatments for genitourinary (GU) tumors and other related serious diseases, leveraging ReviR’s proprietary RNA-targeted technologies.
The collaboration will include multiple oncology targets, with the goal of improving patient outcomes. According to the agreement, Asieris will be utilizing ReviR’s innovative RNA modulation technologies, named BindeR and SpliceR, to identify and develop new therapeutics that target RNA to treat cancer.
ReviR combines computational and high throughput drug discovery technologies with the goal of delivering next generation medicines to patients. Its VoyageR AI platform integrates computational approaches to drug traditionally undruggable RNA targets. Initially, ReviR’s focus is in CNS, oncology, and genetically defined disease indications.
“We are pleased to be collaborating with ReviR, an innovative biopharmaceutical company focused on the development of RNA-targeting small molecule therapies,” said Alice Chen, Ph.D., Vice President, Discovery Biology and Head of Translational Research, at Asieris. “We believe that our in-house R&D expertise on small molecule oncology drug discovery, combined with ReviR’s proprietary RNA-targeted technologies, will speed the benefit to patients. We will continue to adhere to our differentiated R&D strategy, focus on genitourinary tumors and related diseases, expand global reach of our innovation to deliver novel drug products for patients in China and globally.”
“Asieris is a global biopharma company specialized in the development of GU oncology therapies, and we are excited to be working with them to discover new treatments for indications of interests,” stated Paul August, Ph.D., Chief Scientific Officer of ReviR Therapeutics. “Our BindeR and SpliceR platform technologies have the potential to advance therapeutics for undruggable cancer targets, and we believe this collaboration will accelerate the discovery of new treatments for patients.”
“The cooperation with Asieris will provide ReviR with access to the specialized knowledge, and specialized resources to validate the effectiveness of our RNA targeted small molecule platforms,” said Peng Yue, Ph.D., CEO of ReviR Therapeutics. “Importantly such a collaboration will enable us to partake in synergistic endeavors with a highly proficient team of seasoned experts at Asieris, which would undoubtedly lead to novel discoveries and breakthroughs in the small molecule, RNA targeting field. As the first of many partnerships to come for ReviR, we believe that collaboration will greatly augment our efforts to enhance patient outcomes and further the field of cancer research.”
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more